登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688658 证券简称：悦康药业 公告编号：2026-006 悦康药业集团股份有限公司 关于控股股东所持公司部分股份被司法拍卖的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次司法拍卖的主要内容 （一）拍卖标的：京悦永顺持有的悦康药业172万股股票（证券名称：悦康药业，证券代码：688658， 证券性质：无限售流通股）。 1、拍卖时间：2026年3月16日10时至2026年3月17日10时止（延时除外） 2、拍卖地点：在北京市第二中级人民法院京东网司法拍卖网络平台（网址：http://sifa.jd.com/29户名： 北京市第二中级人民法院）上进行公开拍卖活动。 3、本次拍卖为第一次拍卖，展示起拍价：40,170,600元，保证金：8,000,000元，增价幅度：200,000 元。 特别说明：本次拍卖起拍价以拍卖日前20个交易日股票的收盘价均价乘以172万股的金额乘以90%后作 为本次拍卖起拍价。平台公示价格为展示价格，非 ...

格隆汇2月25日丨悦康药业(688658.SH)公布，公司于近日接到控股股东京悦永顺通知，其持有的悦康药 业172万股股票将在北京市第二中级人民法院（简称"北京二中院"）京东网司法拍卖网络平台进行拍 卖。 ...

证券代码：688658 证券简称：悦康药业 公告编号：2026-006 悦康药业集团股份有限公司 关于控股股东所持公司部分股份被司法拍卖的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 悦康药业集团股份有限公司（以下简称"公司"或"悦康药业"）控股股东 阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持有公司股份 153,740,120 股，占公司总股本的比例为 34.16%。截至本公告披露日，本次京悦 永顺持有的本公司 1,720,000 股无限售流通股股票将被司法拍卖。 （一）拍卖标的：京悦永顺持有的悦康药业 172 万股股票（证券名称：悦康 药业，证券代码：688658，证券性质：无限售流通股）。 1、拍卖时间：2026 年 3 月 16 日 10 时至 2026 年 3 月 17 日 10 时止（延时 除外） 2、拍卖地点：在北京市第二中级人民法院京东网司法拍卖网络平台（网址： http://sifa.jd.com/29 户名：北京市第二中级人民法院）上进行公开拍卖活动。 3、本次 ...

（文章来源：第一财经） 悦康药业公告，控股股东阜阳京悦永顺信息咨询有限公司持有的本公司172万股无限售流通股股票将被 司法拍卖。该事项不会影响公司控制权稳定，亦不会对公司日常经营管理造成影响。 ...

悦康药业公告，公司控股股东阜阳京悦永顺信息咨询有限公司所持的172万股股票将被北京市第二中级 人民法院进行司法拍卖。本次拍卖时间为2026年3月16日10时至2026年3月17日10时止，起拍价为 4017.06万元，保证金为800万元，增价幅度为20万元。此次拍卖不会影响公司控制权稳定，也不会对公 司日常经营管理造成影响。 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Core Viewpoint - The announcement details the resignation of two key personnel at Yuyuan Pharmaceutical Group Co., Ltd., including the election of a new employee representative director, ensuring compliance with legal regulations and maintaining board functionality [1][3]. Group 1: Resignation of Directors and Senior Management - Zhang Wei, the employee representative director, resigned for personal reasons but will remain with the company [1]. - Yang Lei, the deputy general manager, resigned due to work adjustments but will also continue to work at the company [1]. - Both resignations will not affect the normal operations of the company, as they have completed the necessary handover procedures [2]. Group 2: Election of Employee Representative Director - On February 13, 2026, Yang Lei was elected as the employee representative director for the third board of directors, with a term lasting until the end of the current board's term [3]. - Yang Lei meets all qualifications and conditions required by relevant laws and the company's articles of association to serve as a director [3]. - The number of directors who are also senior management and employee representative directors does not exceed half of the total board members, complying with legal and regulatory requirements [3].

证券代码：688658 证券简称：悦康药业 公告编号：2026-005 2026 年 2 月 13 日，公司召开了职工代表大会，选举杨磊先生为公司第三届 董事会职工代表董事，任期自 2026 年 2 月 13 日起至第三届董事会任期届满之日 止。 悦康药业集团股份有限公司 关于公司董事、高级管理人员离任 暨补选职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"公司"）董事会于近日收到公司职 工代表董事张伟先生、副总经理杨磊先生递交的书面辞任报告。张伟先生因个人 原因申请辞去公司职工代表董事职务，辞任后仍在公司任职；杨磊先生因工作调 整申请辞去公司副总经理职务，辞任后仍在公司任职，经公司职工代表大会选举 其将担任公司职工代表董事。张伟先生和杨磊先生的前述辞任报告自送达公司董 事会之日起生效。 一、董事、高级管理人员离任情况 | 姓名 | 离任职务 | | 离任时间 | | 原定任期 | | 离任 | 是否继续在 上市公司及 | 具体职务 （如适 | 是否存在 未履行完 | | ...

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].